SCHEMBL4724239

SCHEMBL4724239

OCc1sc2cnccc2c1Nc1ccc2c(c1)CCC2=NO

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 20/20 0.69
MAPK3 P27361 2/20 0.41
MAPK1 P28482 2/20 0.41
BMPR1B O00238 2/20 0.39
CIT O14578 2/20 0.39
RIPK2 O43353 2/20 0.39
STK10 O94804 2/20 0.39
MAP4K4 O95819 2/20 0.39
ABL1 P00519 2/20 0.39
RAF1 P04049 2/20 0.39
ERBB3 P21860 2/20 0.39
JAK1 P23458 2/20 0.39
ACVR1B P36896 2/20 0.39
TGFBR1 P36897 2/20 0.39
CSNK1D P48730 2/20 0.39
CSNK1E P49674 2/20 0.39
MAPK10 P53779 2/20 0.39
MAP2K5 Q13163 2/20 0.39
MAP3K19 Q56UN5 2/20 0.39
MINK1 Q8N4C8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5621621 1.00 BRAF (0.69) BRAFMAPK3MAPK1BMPR1BCIT
SCHEMBL4724237 1.00 BRAF (0.69) BRAFMAPK3MAPK1BMPR1BCIT
SCHEMBL14606525 0.92 BRAF (0.59) BRAFMAPK3MAPK1
SCHEMBL4723987 0.85 BRAF (0.72) BRAFMAPK3MAPK1
SCHEMBL5623106 0.85 BRAF (0.72) BRAFMAPK3MAPK1
SCHEMBL5622357 0.85 BRAF (0.79) BRAFMAPK3MAPK1
SCHEMBL4760810 0.85 BRAF (0.79) BRAFMAPK3MAPK1
SCHEMBL4760812 0.85 BRAF (0.79) BRAFMAPK3MAPK1
SCHEMBL14572039 0.84 BRAF (0.81) BRAFMAPK3MAPK1
SCHEMBL14566739 0.83 BRAF (0.68) BRAFMAPK3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934228-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2008-06-25 EP claimed
WO-2007027855-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-03-08 WO claimed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US claimed
EP-1934228-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2008-06-25 EP disclosed
WO-2007027855-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-03-08 WO disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof BRAF, RAF1, ARAF BRAF 1/4885MAPK3 48/4885MAPK1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.